Leticia Tarilonte
Vice-President, Global Clinical Operations, Brainstorm Cell Therapeutics Leticia has over 24 years of industry experience managing research projects and clinical studies in various roles.
About this speaker
Leticia has over 24 years of industry experience managing research projects and clinical studies in various roles. She started her career in Pharma at Biogen, working collaboratively in an integrated monoclonal antibody research team and then moving to development in clinical operations, where she managed numerous phase I-III clinical trials with Avonex, Tysabri and Tecfidera in diverse therapeutic areas including, gastroenterology, immunology, neurology, and neuropathic pain.
She continued her career at Merck/EMD Serono where she provided strategic and operational expertise in the planning and conduct of several phase III clinical studies with Rebif and Mavenclad in neurology, and with Bavencio in immuno-oncology, which was approved in merkel cell and urothelial carcinoma. Later she served as a Chief of Staff to the Head of Development in Oncology.
After almost 20 years in big Pharma, Leticia continued her career at various biotech companies: first at Kiniksa Pharmaceuticals, where she was responsible for various programs with high complexity in rare diseases, followed by Black Diamond Therapeutics, working on novel precision oncology therapies for patients with genetically defined cancers. Currently she serves as the Vice-President of Global Clinical Operations at Brainstorm Cell Therapeutics, a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, such as ALS.
Leticia also serves as an IRB Member at Yale University, sits on the Advisory Board of Leal Health, an AI-powered decision-making support platform dedicated to expediting patient access to all available advanced cancer treatments, and is the Chair and President of the New England Chapter of the Association of Clinical Research Professionals (ACRP).
Leticia earned her Bachelor’s degree in Biomedical Laboratory and Clinical Sciences from the School of Medicine at Boston University, followed by a Master’s degree in Regulatory Affairs and Health Policy from the Massachusetts College of Pharmacy and Health Sciences in Boston.
